Temple acquires Longevous longevity practice
Analysis based on 19 articles · First reported Aug 27, 2026 · Last updated Aug 27, 2026
The acquisition strengthens Temple's clinical credibility ahead of its wearable launch, potentially boosting investor confidence and consumer interest. It may also signal growth in the longevity and healthtech sectors, positively impacting related startups and investors.
Temple, a healthtech wearable startup founded by Zomato, has acquired Longevous, a London-based evidence-based longevity medicine practice. The acquisition brings Longevous founders Dr Robert Mohr and Dr Avi Roy, along with their team, into Temple full-time. Mohr will serve as Chief Medical Officer, and Roy as Head of Science. The deal was announced by Goyal on X on August 27, 2026. Financial terms were not disclosed. Longevous will continue to operate as part of Temple, with its founders continuing to look after existing clients. The acquisition adds clinical and scientific expertise to Temple ahead of the planned launch of its wearable device, which tracks cerebral blood flow and oxygenation. The device features a proprietary metric called Entropy. Temple raised $54 million in February 2026 at a valuation of about $190 million, and its valuation doubled to $375 million following a secondary share sale in July 2026.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard